CRVO
CervoMed Inc.
$4.52
+82.26%
$41.8M
No data for this timeframe.
Vol
Market Cap$41.8M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders14 funds
Inst. Value$5.0M
Inst. Activity1 buys / 1 sells
Insider Activity3B / 0S
Insider Net $$3.0M
Reddit Sentiment50° Neutral
SEC Reports8
Press Releases1
Recent Activity
Jun 15, 2026
SEC
CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation has been made available on its webs
8-K — Impact 2/10
Jun 12, 2026
other
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
<p>BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotec
Jun 11, 2026
Insider
BOGER JOSHUA S bought 955,414 shares
Director @ $3.14 ($3.0M)
Jun 11, 2026
Insider
BOGER JOSHUA S bought 955,414 shares
Director
Jun 11, 2026
Insider
BOGER JOSHUA S bought 955,414 shares
Director
Jun 10, 2026
SEC
CervoMed Inc. (CRVO) entered into a securities purchase agreement to sell $10.55 million in units at $3.14/unit, compris
8-K — Impact 7/10
May 18, 2026
SEC
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9M, providing runway
8-K — Impact 6/10
Inst.
MORGAN STANLEY — ADD
739,892 shares ($2.9M)
Price Targets
$19.50
+331.4% upside
Strong Buy
Current $4.52
Low $9.00
Median $20.50
High $27.00
6 analysts
$9.00
$27.00
Analyst Ratings
2Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 22, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Roth Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.79 ▼ -35.0% | $-0.98 — $-0.39 | -12% YoY | 6 |
| Next Q | $-0.58 ▼ -12.8% | $-1.04 — $-0.30 | 30% YoY | 6 |
| Current FY | $-2.68 ▼ -12.3% | $-4.34 — $-1.75 | 10% YoY | 6 |
| Next FY | $-2.42 ▼ -42.8% | $-4.60 — $-1.36 | 10% YoY | 5 |
Latest Reports
NEUTRAL
8-K
2/10
CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation has been made available on its webs
Jun 15, 2026
BEARISH
8-K
7/10
CervoMed Inc. (CRVO) entered into a securities purchase agreement to sell $10.55 million in units at $3.14/unit, compris
Jun 10, 2026
MIXED
Press
6/10
CervoMed reported full-year 2025 financial results and corporate updates, highlighting positive Phase 2b data for its le
Mar 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $2.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $251.8K | — |
| BlackRock, Inc. | $203.5K | TRIM |
| VANGUARD FIDUCIARY TRUST CO | $142.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | BOGER JOSHUA | BUY | $3.0M |
| Jun 11, 2026 | BOGER JOSHUA | BUY | $0.00 |
| Jun 11, 2026 | BOGER JOSHUA | BUY | $0.00 |
| Jun 8, 2026 | ALAM JOHN | A | $0.00 |
| Jun 8, 2026 | Hollingsworth Jane | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
14 institutional holders with $5.0M total value (1,269,902 shares) as of 2026-Q1. Top holders: MORGAN, VANGUARD, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 739,892 | $2.9M | 58.3% | ADD +55.9% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 316,202 | $1.2M | 24.9% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 63,904 | $251.8K | 5.0% | — |
| 4 | BlackRock, Inc. | 51,660 | $203.5K | 4.1% | TRIM -53.1% |
| 5 | VANGUARD FIDUCIARY TRUST CO | 36,151 | $142.4K | 2.8% | — |
| 6 | STATE STREET CORP | 20,527 | $80.9K | 1.6% | NEAR_EXIT -83.1% |
| 7 | Russell Investments Group, Ltd. | 16,090 | $63.4K | 1.3% | DOUBLED +8159.4% |
| 8 | HighTower Advisors, LLC | 11,265 | $44.4K | 0.9% | — |
| 9 | FMR LLC | 11,040 | $43.5K | 0.9% | DOUBLED +1007.9% |
| 10 | Vanguard Global Advisers, LLC | 2,597 | $10.2K | 0.2% | — |
| 11 | ROYAL BANK OF CANADA | 283 | $1.0K | 0.0% | DOUBLED +1192.7% |
| 12 | NISA INVESTMENT ADVISORS, LLC | 251 | $989.00 | 0.0% | DOUBLED +457.8% |
| 13 | CWM, LLC | 39 | $154.00 | 0.0% | TRIM -40.0% |
| 14 | DANSKE BANK A/S | 1 | $4.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 474,494 | 739,892 | +55.9% | $2.9M | 2026-Q1 |
| CWM, LLC | TRIM | 65 | 39 | -40.0% | $154.00 | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 17,108 | 12,512 | -26.9% | $98.8K | 2025-Q4 |
| CWM, LLC | TRIM | 144 | 65 | -54.9% | $1.00 | 2025-Q4 |
| BlackRock, Inc. | TRIM | 104,049 | 48,832 | -53.1% | $395.1K | 2025-Q3 |
| UBS Group AG | TRIM | 5,593 | 3,376 | -39.6% | $27.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 880 | 12 | -98.6% | $97.00 | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 417 | 1 | -99.8% | $8.00 | 2025-Q3 |
| CWM, LLC | NEAR_EXIT | 838 | 144 | -82.8% | $1.00 | 2025-Q3 |
| STATE STREET CORP | NEAR_EXIT | 112,056 | 18,927 | -83.1% | $119.0K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 177 | 2,288 | +1192.7% | $14.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 2,579 | 131 | -94.9% | $823.00 | 2025-Q2 |
| BARCLAYS PLC | NEAR_EXIT | 5,881 | 417 | -92.9% | $3.00 | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 50,628 | 137,057 | +170.7% | $1.3M | 2025-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 229 | 18,914 | +8159.4% | $173.1K | 2025-Q1 |
| FMR LLC | DOUBLED | 1,052 | 11,655 | +1007.9% | $106.6K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 43,365 | 6,787 | -84.3% | $62.1K | 2025-Q1 |
| RHUMBLINE ADVISERS | ADD | 4,304 | 5,830 | +35.5% | $53.3K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 5,260 | 3,665 | -30.3% | $33.5K | 2025-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 45 | 251 | +457.8% | $2.3K | 2025-Q1 |
| CWM, LLC | DOUBLED | 24 | 937 | +3804.2% | $9.00 | 2025-Q1 |
| CWM, LLC | NEAR_EXIT | 59,120 | 24 | -100.0% | — | 2024-Q4 |
| ROYAL BANK OF CANADA | TRIM | 766 | 213 | -72.2% | — | 2024-Q4 |
| UBS Group AG | DOUBLED | 2,537 | 43,365 | +1609.3% | $101.5K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,886 | 5,260 | +35.4% | $12.3K | 2024-Q4 |
12 unique insiders with 17 transactions. Net insider value: $3.0M ($3.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | BOGER JOSHUA S | Director | BUY | 955,414 | $3.14 | $3.0M |
| Jun 11, 2026 | BOGER JOSHUA S | Director | BUY | 955,414 | — | — |
| Jun 11, 2026 | BOGER JOSHUA S | Director | BUY | 955,414 | — | — |
| Jun 8, 2026 | ALAM JOHN J | CEO & President | AWARD | 8,150 | — | — |
| Jun 8, 2026 | Hollingsworth Jane H | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | Gregoire Sylvie | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | BOGER JOSHUA S | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | Sabbagh Marwan | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | Poulton Jeffrey V. | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | Quigley David | Director | AWARD | 8,150 | — | — |
| Jun 8, 2026 | ZAVRL FRANK | Director | AWARD | 8,150 | — | — |
| Feb 11, 2026 | Winton Matthew | Chief Commercial and Business | AWARD | 30,000 | — | — |
| Feb 11, 2026 | ALAM JOHN J | CEO & President | AWARD | 75,000 | — | — |
| Feb 11, 2026 | De Rosch Mark | EVP, RA and GA and PgM | AWARD | 30,000 | — | — |
| Feb 11, 2026 | ELDER WILLIAM ROBERT | CFO, GC & Secretary | AWARD | 30,000 | — | — |
| Feb 11, 2026 | Blackburn Kelly | EVP, Clinical Development | AWARD | 30,000 | — | — |
| Feb 11, 2026 | Gregoire Sylvie | Director | AWARD | 75,000 | — | — |
8 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 2 mixed, 2 neutral. Avg impact: 5.6/10.
NEUTRAL
8-K
2/10
CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation has been made a
Jun 15, 2026
BEARISH
8-K
7/10
CervoMed Inc. (CRVO) entered into a securities purchase agreement to sell $10.55 million in units at
Jun 10, 2026
BEARISH
8-K
6/10
CervoMed reported Q1 2026 net loss of $8.0M (vs $4.9M Q1 2025) with cash burn reducing cash to $12.9
May 18, 2026
MIXED
PRESS-RELEASE
6/10
CervoMed reported Q1 2026 EPS of -$0.86, beating consensus of -$0.98 by 12.2%, but net loss widened
May 18, 2026
BULLISH
8-K
7/10
CervoMed announced positive Phase 2b trial data showing neflamapimod increased basal forebrain volum
Apr 22, 2026
MIXED
PRESS-RELEASE
6/10
CervoMed Inc. (CRVO) presented new MRI data from its RewinD-LB Phase 2b trial showing that neflamapi
Apr 22, 2026
NEUTRAL
8-K
4/10
CervoMed Inc. announced a clinical update on its neflamapimod program for dementia with Lewy bodies
Apr 7, 2026
BULLISH
8-K
7/10
CervoMed announced the successful completion of a Phase 1 study for a new, stable crystal form of it
Mar 4, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 2 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$19.50 mean target
+331.4% upside
Strong Buy (1.00)
$9.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $4.52 |
| Target Low | $9.00 |
| Target Mean | $19.50 |
| Target Median | $20.50 |
| Target High | $27.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.79 | $-0.98 | $-0.39 | -12.1% | -35.0% | 1↑ 3↓ | $0.0B | -97.6% | 6 |
| Next Q 2026-09-30 |
$-0.58 | $-1.04 | $-0.30 | 30.4% | -12.8% | 2↑ 2↓ | $0.0B | -77.9% | 6 |
| Current FY 2026-12-31 |
$-2.68 | $-4.34 | $-1.75 | 10.2% | -12.3% | 2↑ 1↓ | $0.0B | -94.3% | 6 |
| Next FY 2027-12-31 |
$-2.42 | $-4.60 | $-1.36 | 9.7% | -42.8% | 1↑ 2↓ | $0.0B | 212.5% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.785 | |
| 7d ago | $-0.785 | |
| 30d ago | $-0.581 | -0.204 |
| 60d ago | $-0.581 | -0.204 |
| 90d ago | $-0.502 | -0.283 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Feb 18, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 2 | 11 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
6 mentions
0 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 16, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 16, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 16, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 16, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| Jan 29, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CRVO 100% Up
▲ 1
💬 0
⚡ 0.5
CRVO
▲ 1
💬 0
⚡ 0.5
$CRVO – CervoMed Inc. - (Spoiler I am down 43%)
▲ 1
💬 0
⚡ 0.0
Jun 12, 2026
other
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
<p>BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-rela
Jun 10, 2026
earnings
CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
<p align="center"><em>Additional funding will extend anticipated runway into second quarter of 2027 </em></p>
Jun 7, 2026
Clinical Trial
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase Phase 2 — COMPLETED
Jun 7, 2026
clinical_trial_readout
Results Pending: neflamapimod (Phase 2) — Completed 88d ago
Trial: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: EIP Pharma Inc
Phase: Phase 2 | Completed: 2026-03-11
Cond
May 19, 2026
earnings_calendar
CRVO Q1 2026 Earnings Scheduled — 2026-05-19
May 18, 2026
earnings
CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
<p align="center"><em>Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with dementia with Lewy bodies i
May 11, 2026
earnings_calendar
CRVO Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
clinical_trial_readout
Results Pending: neflamapimod (Phase 2) — Completed 58d ago
Trial: A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Sponsor: EIP Pharma Inc
Phase: Phase 2 | Completed: 2026-03-11
Cond
May 6, 2026
Clinical Trial
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Phase Phase 2 — COMPLETED
Apr 22, 2026
earnings
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
<p align="center"><em>Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease p
Apr 7, 2026
routine
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
<p align="center"><em>Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and fi
Mar 19, 2026
other
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
<p align="center"><em>New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheime
Mar 17, 2026
earnings
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
<p align="center"><em>Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026</em></p>
Mar 16, 2026
earnings_calendar
CRVO Q4 2025 Earnings After Market Close — 2026-03-16
Mar 5, 2026
other
CervoMed to Participate in Upcoming Investor Conferences
<p>BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-rel
Mar 4, 2026
other
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies